Turkey Tail PSK, PSP & Cancer Adjunct Therapy

PSK (polysaccharide-K, brand name Krestin) and PSP (polysaccharopeptide) are the two best-validated medicinal mushroom extracts in the world. PSK was approved by the Japanese Ministry of Health as a prescription cancer adjunct in 1977 and at its peak captured approximately one-quarter of the entire Japanese national pharmaceutical cancer budget. PSP, isolated from a separate Chinese strain at Shanghai Teacher's University in 1983, became standard adjunct therapy in Chinese oncology. Over forty years, dozens of randomized trials have established statistically significant survival improvements in gastric, colorectal, lung, breast, and esophageal cancer when these extracts are added to surgery, chemotherapy, or radiotherapy. This page walks through the pivotal clinical trials, the proposed mechanisms, the practical dosing protocols, and the limits of the evidence.

Table of Contents

  1. What PSK and PSP Actually Are
  2. Regulatory History (Japan, China, the West)
  3. The Nakazato Gastric Cancer Trial (Lancet 1994)
  4. Colorectal Cancer Trials (Sakai & Ohwada)
  5. The Bastyr Phase I Breast Cancer Trial (Torkelson 2012)
  6. Lung Cancer Adjunct (Hayakawa, Tsang)
  7. Mechanism of Action
  8. Practical Protocols & Dosing
  9. Limits of the Evidence
  10. Cautions and Drug Interactions
  11. Key Research Papers
  12. Connections

What PSK and PSP Actually Are

Both PSK and PSP are protein-bound polysaccharide complexes extracted from Trametes versicolor mycelium grown in submerged liquid culture. The polysaccharide backbone is a beta-glucan with primary beta-1,4 linkages and beta-1,3 / beta-1,6 branches, complexed with a small protein moiety (approximately 25-38% protein by weight for PSP, 35% for PSK). The protein component appears important for solubility and possibly for receptor binding.

The two extracts differ in three respects:

Modern over-the-counter Turkey Tail supplements sold in the West are usually neither PSK nor PSP. They are typically dual-extracted (hot-water + ethanol) preparations of the wild fruiting body, with beta-glucan content varying from less than 5% to as high as 45% depending on the manufacturer. The clinical-trial evidence base summarized below applies most directly to the Japanese and Chinese prescription preparations, and only by inference to over-the-counter dual extracts — though the upstream mechanism (beta-glucan engagement of dectin-1 on dendritic cells) is shared.

Back to Table of Contents

Regulatory History (Japan, China, the West)

PSK's clinical journey began at Kureha Chemical Industry in Japan in 1965. By 1977 it had completed sufficient Phase III trials to receive approval from the Japanese Ministry of Health, Labour and Welfare as a prescription adjuvant for gastric, colon, and lung cancers. By the mid-1980s PSK was generating annual sales of approximately $400-500 million USD and accounted for an estimated 25% of Japan's national cancer drug expenditure — an extraordinary commercial penetration for any single oncology agent.

PSP's parallel approval in China followed a similar arc. Yang Qing-Yao at Shanghai Teacher's University isolated PSP in 1983 from the Cov-1 strain, demonstrated antitumor activity in murine models, and shepherded it through Chinese regulatory approval as a Class II prescription medicine for cancer in 1987. PSP became standard adjunct therapy in Chinese oncology and remains so today.

The Western regulatory landscape is different. PSK has never been approved as a prescription drug by the FDA or EMA. Memorial Sloan Kettering Cancer Center includes Turkey Tail in its integrative oncology monograph and acknowledges the supportive trial data, but does not formally recommend supplementation in NCCN treatment guidelines. The NIH NCCIH summary states that "there is some evidence" supporting use as a cancer adjunct but that "more rigorous trials are needed." This is the gap between the Asian regulatory acceptance and the Western evidentiary standard for prescription approval — a gap that has more to do with trial-design conventions (Asian trials often used historical controls, open-label designs, or non-standard endpoints by FDA standards) than with effect size.

Back to Table of Contents

The Nakazato Gastric Cancer Trial (Lancet 1994)

The single most cited clinical trial of PSK is Nakazato H et al., published in The Lancet in 1994. The design: 262 Japanese patients with curatively resected gastric cancer (Stage II or III) were randomized after surgery to either standard chemotherapy alone (mitomycin C + 5-FU then 5-FU oral maintenance) or the same chemotherapy plus 3 g/day oral PSK for at least one year.

Results at 5-year follow-up:

The Nakazato trial established the template for subsequent PSK trials in other cancers: surgically resectable disease, standard chemotherapy in both arms, PSK added orally at 3 g/day for at least one year, primary endpoint disease-free or overall survival at 5 years. A pre-PSK skin-test reactivity has continued to show up as a positive predictor of response across multiple trials — suggesting that PSK is most effective in patients whose baseline immune competence is still partially intact and least effective in profoundly immunosuppressed patients.

Back to Table of Contents

Colorectal Cancer Trials (Sakai & Ohwada)

The colorectal cancer literature is the most extensive for PSK, with five major Japanese randomized trials pooled in Sakai et al. 2008. Across approximately 1,800 patients with Dukes B or C colorectal cancer (American AJCC Stage II-III) randomized to standard adjuvant chemotherapy with or without PSK:

The Ohwada 2006 trial in the British Journal of Cancer extended this with a cleaner design: 205 patients with Stage II or III colorectal cancer received tegafur/uracil (UFT) standard adjuvant chemotherapy with or without PSK 3 g/day for 24 months. The 5-year disease-free survival was 75% in the PSK arm vs 59% in the control arm (p=0.016) — a 16-percentage-point absolute improvement.

The colorectal data are arguably the most compelling subset of PSK evidence: multiple independent trials, large patient numbers, consistent direction of effect, and biological plausibility from the gut-localized polysaccharide-immune mechanism.

Back to Table of Contents

The Bastyr Phase I Breast Cancer Trial (Torkelson 2012)

The Torkelson 2012 ISRN Oncology trial is significant as the first US FDA-monitored Phase I clinical trial of Trametes versicolor mushroom extract in any cancer indication. Conducted at Bastyr University's research institute in Washington, the trial enrolled 11 women with stage I-III breast cancer who had completed primary chemotherapy and radiation. Patients received a standardized whole-mushroom Trametes versicolor extract at three escalating doses (3 g/day, 6 g/day, 9 g/day) for 6 weeks.

Findings:

The Bastyr trial was small, single-arm, and limited to surrogate immune endpoints (no survival data). It does not prove clinical benefit. But it does establish that whole-mushroom dual-extract Trametes versicolor (not pharmaceutical PSK) can produce measurable immune effects at orally tolerated doses in post-chemotherapy patients, supporting the inference that over-the-counter dual extracts likely share at least some of the upstream immune-modulating activity of pharmaceutical PSK.

Back to Table of Contents

Lung Cancer Adjunct (Hayakawa, Tsang)

Lung cancer evidence comes primarily from two trials. Hayakawa 1993 (Anticancer Research) randomized 169 Japanese patients with non-small cell lung cancer who had completed radical radiotherapy to oral PSK 3 g/day or placebo. The 5-year survival in the PSK arm was 26% (stage I/II) and 22% (stage III), compared with 8% in stage III controls. The hazard reduction was most striking in stage III locally advanced disease.

Tsang KW et al. 2003 (Respiratory Medicine) conducted a randomized trial of PSP in 34 patients with advanced (stage III/IV) NSCLC. PSP slowed disease progression and improved quality of life over 28 days of administration. The trial was small, but the mechanism is consistent: PSP NK cell potentiation can slow but does not reverse advanced disease.

The 2012 Eliza et al. systematic review in Recent Patents on Inflammation & Allergy Drug Discovery pooled multiple Yun Zhi (Coriolus versicolor) trials across gastric, colorectal, breast, and lung cancer and concluded that adjunctive Yun Zhi was associated with a statistically significant 9% absolute increase in 5-year survival overall, with the largest benefit in breast (15%) and lung (8%) cancer.

For information on the cancers themselves, see our Oncology hub.

Back to Table of Contents

Mechanism of Action

The proposed mechanisms of PSK and PSP antitumor activity are layered:

  1. Dectin-1 engagement on macrophages, dendritic cells, and neutrophils — the beta-1,3 / beta-1,6 glucan structures bind dectin-1, triggering Syk-CARD9 signaling and activation of pattern-recognition immunity. This is the same receptor that recognizes invading fungal pathogens, and the host response is appropriately Th1-biased.
  2. NK cell potentiation — activated dendritic cells secrete IL-12, IL-15, and IL-18 which prime natural killer cell cytotoxicity. NK cells are the primary innate cellular response to tumor cells lacking MHC class I (a common immune-evasion mechanism in malignancy), making them a particularly relevant effector population.
  3. Restoration of immune competence after cytotoxic therapy — the most compelling clinical use case is restoring lymphocyte and NK cell function in patients depleted by chemotherapy or radiotherapy, where the slow recovery itself may permit residual tumor cells to expand.
  4. TLR4 co-stimulation — PSP and PSK can also engage Toll-like receptor 4, contributing additional myeloid cell activation independent of dectin-1.
  5. Direct cytotoxicity (weak) — in vitro studies show modest direct cytotoxicity of PSK against several tumor cell lines, but the in vivo concentrations required exceed plausible serum levels. The dominant mechanism is immune-mediated.
  6. Microbiome-mediated immune signaling — as discussed in our gut microbiome page, unabsorbed beta-glucans are fermented in the colon and shape the gut bacterial community in ways that feed back to systemic immune tone.

Back to Table of Contents

Practical Protocols & Dosing

For patients considering Turkey Tail as a cancer adjunct, the dosing conventions from the clinical literature are:

It is essential to coordinate use with the patient's oncology team. PSK and PSP have well-documented safety profiles, but the principle of communicating all concurrent therapies to the treating oncologist applies.

Back to Table of Contents

Limits of the Evidence

The PSK / PSP cancer adjunct evidence has several important limitations worth stating plainly:

Back to Table of Contents

Cautions and Drug Interactions

For more on integrative oncology resources, see Immune Boosting.

Back to Table of Contents

Key Research Papers

  1. Nakazato H et al. (1994). Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. The Lancet 343(8906):1122-1126. — PubMed
  2. Sakai T et al. (2008). PSK adjuvant therapy in colorectal cancer (meta-analysis of three randomized trials). Cancer Biotherapy and Radiopharmaceuticals. — PubMed
  3. Ohwada S et al. (2006). Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer. British Journal of Cancer 95(11):1496-1504. — PubMed
  4. Torkelson CJ et al. (2012). Phase I clinical trial of Trametes versicolor in women with breast cancer. ISRN Oncology. — PubMed
  5. Hayakawa K et al. (1993). Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Research 13(5C):1815-1820. — PubMed
  6. Tsang KW et al. (2003). Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer. Respiratory Medicine 97(6):618-624. — PubMed
  7. Eliza WL et al. (2012). Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent Patents Inflamm Allergy Drug Discov. — PubMed
  8. Sun Z et al. (1999). Adjuvant PSP capsule in cancer patients (RCT). Cancer Biotherapy & Radiopharmaceuticals. — PubMed
  9. Kanazawa M et al. (2004). PSK effects on dendritic cell function in gastric cancer patients. Anticancer Research. — PubMed
  10. Standish LJ et al. (2008). Trametes versicolor mushroom immune therapy in breast cancer. Journal of the Society for Integrative Oncology. — PubMed
  11. Sakagami H et al. (1991). PSK (krestin): mechanism of antitumor action. In Vivo. — PubMed
  12. Cui J, Chisti Y (2003). Polysaccharopeptides of Coriolus versicolor: physiological activity, uses, and production. Biotechnology Advances 21(2):109-122. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents